Switzerland· 65643003
Uptravi 400 mcg, Filmtabletten
A selexipag product containing selexipagum, registered in Switzerland by Janssen-Cilag AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Selexipag is registered in 13 of 19 countries.
Countries holding a registration under ATC B01AC27 (selexipag), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 8 of them publish a price we can compare per daily dose
Selexipag · ATC B01AC27
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of selexipag costs, country by country.
Normalised to the WHO defined daily dose (1.8 mg), the median price runs from $809.99 in Switzerland to $1232.99 in Italy — a ×1.5 gap.
- Switzerland: $809.99 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Selexipag · price per daily dose (1.8 mg)
USD · FX 28 Sept 2026
- IT Italy$1232.99
- CH Switzerland$809.99
The record
At a glance
Swissmedic (Switzerland)- Active substance
- selexipagum
- Manufacturer
- Janssen-Cilag AG
- Country
- Switzerland (CH)
- ATC code
- B01AC27
- ATC class
- Selexipag
- Defined daily dose
- 1.8 mg, O
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin768065643003660 StkCHF 4854.3
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
237 interactions on record for selexipag.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Selexipag · interactions on record
237 records
- 1 severe
- 232 moderate
- 4 minor
Most severe, free to view
- GemfibrozilC10AB04severe
- PapaverineA03AD01moderate
- MannitolA06AD16moderate
- GlycerolA06AX01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Selexipag in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwedenSelexipag Accord 400 mikrogram Filmdragerad tablettAccord Healthcare B.V.
- NetherlandsSelexipag Abdi 400 microgram filmomhulde tablettenAbdi Farma GmbH
- PolandSelexipag AccordAccord Healthcare Polska Sp. z o.o.
- CzechiaSELEXIPAG ACCORDACCORD HEALTHCARE POLSKA Sp. z o.o., Varšava
- SpainSELEXIPAG ACCORD 400 MICROGRAMOS COMPRIMIDOS RECUBIERTOS CON PELICULA EFGAccord Healthcare S.L.U.
- IrelandSelexipag Accord 1 400 microgram film-coated tabletsAccord Healthcare Ireland Ltd.
- United StatesSelexipagZydus Pharmaceuticals (USA) Inc.
- NorwayUptraviJanssen-Cilag International N.V.
Authorised across Europe · EMA
The same active substance is authorised in 19 EEA countries. Names it is sold under:
- Austria · Selexipag Ratiopharm
- Cyprus · Selexipag Accord
- Denmark · Selexipag Accord, Selexipag Stada
- Estonia · Selexipag Stada
- Spain · Selexipag Accord, Selexipag Stada
- Greece · Xipeno
- Croatia · Seleksipag Accord
- Ireland · Selexipag Accord, Selexipag Clonmel
- Iceland · Selexipag Stada, Uptravi
- Italy · Selexipag Accord, Selexipag Eg
- Liechtenstein · Uptravi
- Lithuania · Selexipag Stada
- Latvia · Selexipag Stada
- Malta · Selexipag Clonmel
- Netherlands · Seleksipag Accord, Selexipag Abdi
- Norway · Selexipag Accord, Selexipag Stada
- Poland · Selexipag, Selexipag Accord
- Portugal · Selexipag Accord, Selexipag Teva
- Sweden · Selexipag, Selexipag Accord
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fc7b19f9-6dc7-4472-b55c-e2dc39de872e GET /v1/drugs/fc7b19f9-6dc7-4472-b55c-e2dc39de872e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "selexipagum 0.4 mg",
"valid_from": "2016-11-01",
"limitations": "[{\"description\":\"Pulmonale Hypertonie bei Patienten mit NYHA III und IV (Einteilung nach New York Heart Association).\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2016-11-01\"}]",
"galenic_form": "Filmtabl 400 mcg",
"therapeutic_area": null,
"sl_inclusion_date": "2016-11-01",
"self_retention_pct": 10
}See everything about selexipag.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.